Alternative splicing of the cell fate determinant Numb in hepatocellular carcinoma.
Alternative splicing of the cell fate determinant Numb in hepatocellular carcinoma.
复制标题
DOI:
10.1002/hep.27923
复制
发表时间:
2015-10
期刊:
影响因子:
--
通讯作者:
Neckers L
中科院分区:
文献类型:
--
作者:
Lu Y;Xu W;Ji J;Feng D;Sourbier C;Yang Y;Qu J;Zeng Z;Wang C;Chang X;Chen Y;Mishra A;Xu M;Lee MJ;Lee S;Trepel J;Linehan WM;Wang X;Yang Y;Neckers L
The cell fate determinant Numb is aberrantly expressed in cancer. Numb is alternatively spliced with one isoform containing an extended proline rich region (PRRL) compared to the other (PRRS). PRRL was recently reported to enhance proliferation of breast and lung cancer cells. However, the importance of Numb alternative splicing in hepatocellular carcinoma (HCC) remain unexplored. We report here that Numb PRRL expression is increased in HCC and is associated with early recurrence and reduced overall survival after surgery. In a panel of HCC cell lines, PRRL generally promotes and PRRS suppresses proliferation, migration, invasion and colony formation. PRRS knockdown leads to increased Akt phosphorylation and c-Myc expression, and Akt inhibition or c-Myc silencing dampens the proliferative impact of Numb PRRS knockdown. In the cell models explored in this study, alternative splicing of Numb PRR isoforms is coordinately regulated by the splicing factor Rbfox2 and the kinase SRPK2. Rbfox2 knockdown causes accumulation of PRRL while SRPK2 knockdown causes accumulation of PRRS. SRPK2 subcellular location is regulated by the molecular chaperone Hsp90, and Hsp90 inhibition or knockdown phenocopies SRPK2 knockdown in promoting accumulation of Numb PRRS. Finally, HCC cell lines that predominately express PRRL are differentially sensitive to Hsp90 inhibition. Our data suggest that alternative splicing of Numb may provide a useful prognostic biomarker in HCC and is pharmacologically tractable.